Academic Achievements 1. BN-type bioprosthetic valve and its clinical application won the Third Prize of the National Science and Technology Progress Award in 1987 (led by Professor Zhu Xiaodong), as a major participant. 2. Research on GK-type artificial mechanical valve won the First Prize of Scientific and Technological Achievements of the Chinese Academy of Medical Sciences and Peking Union Medical College in 1988 (led by Professor Zhu Xiaodong), as a major participant. 3. Research on hydrodynamic performance of artificial heart valves won the Second Prize of the Research Encouragement Fund of the Ministry of Health in 1987 and 1988, as the first completer. 4. Research on the basic and clinical effects of artificial heart valves won the Outstanding Contribution Master's Degree Student Award from the State Education Commission and the Academic Degrees Committee of the State Council in 1991, as the sole completer. 5. Research on the basic and clinical effects of artificial heart valves won the Outstanding Contribution Master's Degree Student Award from the Chinese Academy of Medical Sciences and Peking Union Medical College in 1991, as the sole completer. 6. Report on surgical treatment of 175 cases of tetralogy of Fallot in children aged 5 months to 5 years won the Second Prize of Medical Science and Technology Achievements of the Chinese Academy of Medical Sciences and Peking Union Medical College in 1993 and 1994, as the first completer. 7. Research on surgical efficacy and high-risk factor analysis of tetralogy of Fallot in children aged 3 months to 5 years won the Second Prize of Science and Technology Progress of the Ministry of Health in 1998, as the first completer. 8. Surgical treatment of complex congenital heart disease in infants and young children won the Second Prize of Beijing Science and Technology Progress in 1998, as the second completer. 9. Clinical research on improving the efficacy of radical correction of tetralogy of Fallot and analysis of high-risk factors won the Third Prize of the National Science and Technology Progress Award in 1999, as the first completer. 10. Treatment and applied research on correction of congenital cardiac malformations in children through right lateral small incision won the Second Prize of Beijing Science and Technology Progress in 2000, as the first completer. 11. Basic and clinical experimental research on improving the surgical efficacy of complex congenital heart disease in infants and young children won the Second Prize of Chinese Medical Science and Technology Progress in 2002, as the first completer. 12. Clinical and experimental research on improving the surgical efficacy of severe congenital heart disease in infants and young children won the Second Prize of Wu Jieping Medical Research - Janssen Pharmaceutical Research in 2002, as the first completer. 13. Clinical and basic series research on improving the surgical efficacy of severe congenital heart disease in infants and young children won the Second Prize of the National Science and Technology Progress Award in 2004, as the first completer. Honors and Awards Honorary Awards 1. In 1991, was rated as an outstanding contribution master's degree student by the State Education Commission and the Academic Degrees Committee of the State Council. 2. In 1995, was rated as a cross-century outstanding talent by the State Education Commission, and enjoyed special state allowance in 1996. 3. In 1997, received the Outstanding Youth Science Fund from the National Natural Science Foundation of China. 4. In 1997, was selected for the "National Hundred, Thousand and Ten Thousand Talent Project" first and second level talent plan of the Ministry of Labor and Personnel. 5. In 2000, received the Beijing Meritorious Labor Model award. 6. In 2004, was rated as a young and middle-aged expert with outstanding contributions by the Ministry of Health. 7. In 2006, received the Outstanding Contribution Award of the Jiusan Society. 8. In 2011, was a leading talent in the Beijing health system. Professor Liu Yinglong has been engaged in cardiovascular surgery medical, teaching, and research work since 1974. He is a famous cardiac surgery expert in China and a world-renowned pediatric congenital heart disease surgery expert. He has made outstanding contributions to the tertiary prevention and treatment of heart valves and congenital heart disease. He has been responsible for and guided more than 20 national major scientific research projects during the "Ninth Five-Year Plan", "Tenth Five-Year Plan", and "Eleventh Five-Year Plan" periods. He has published more than 200 papers, including more than 100 SCI-indexed papers as the first author and corresponding author, authored 1 book, participated in authoring 6 books, and trained 25 master's students, 52 doctoral students, and 12 postdoctoral fellows. In 1983, under the guidance of Academician Zhu Xiaodong, he conducted in vivo and in vitro hemodynamic research on China's self-developed BN-type bovine pericardial valve and GK mechanical valve, reducing the mortality rate of heart valve replacement surgery from 17.8% before 1986 to 5%. His own mortality rate for high-difficulty valve surgeries such as double valve replacement, valve plasty, and secondary valve replacement was less than 2.13%. He has unique insights into valve plasty and secondary and multiple valve replacement surgeries. Since 1994, Professor Liu Yinglong has been committed to the research of pediatric congenital heart disease, especially the clinical and basic research of severe complex congenital heart disease in infants and young children. He has completed more than 20,000 heart surgeries and innovated more than 10 techniques, including: research on high-risk factors for radical correction of tetralogy of Fallot in infants and young children, pioneering right subaxillary small incision surgery for congenital heart disease, proposing diagnostic treatment for congenital heart disease with severe pulmonary hypertension, perioperative cardiopulmonary protection for severe congenital heart disease, and surgical correction of transposition of the great arteries in older patients. He has visited more than 100 hospitals in more than 20 provinces and cities in China and overseas for academic exchanges and surgical demonstrations. He has actively promoted the establishment of a tertiary prevention and treatment network system for congenital heart disease. Since 1995, when he proposed to the Ministry of Science and Technology to establish a project for tertiary prevention and treatment of congenital heart disease, it has been nearly 30 years. Primary prevention: prevention of teratogenic factors of congenital heart disease, including external factors - both parents avoiding viral infection and contact with harmful substances, and internal factors - genetic factors, etc. Secondary prevention: fetal cardiac ultrasound for mothers at 4 months of pregnancy, and eugenic guidance for children with complex and severe congenital heart disease that cannot be completely corrected. Tertiary prevention: surgical treatment for children born with congenital heart disease. We jointly held ultrasound physician training classes with the Ministry of Health, conducted multiple congenital heart disease training classes across the country every year, and established congenital heart disease prevention and treatment training bases, so that the popular science knowledge of tertiary prevention and treatment of congenital heart disease has been widely disseminated, improving the level of tertiary prevention and treatment of congenital heart disease in various regions. During the Ninth Five-Year Plan, Tenth Five-Year Plan, and Eleventh Five-Year Plan periods, the Ministry of Science and Technology and the Ministry of Health established a special fund for "Key Technologies for Family Planning and Healthy Births" in clinical discipline key projects, with congenital heart disease prevention and treatment as a key funded project. The research projects I am responsible for include: Capital Medical Development Research Fund "Key Technologies for Tertiary Prevention of Congenital Heart Disease in Beijing", Beijing Health System Leading Talent Training Program "Establishment, Popularization and Improvement of the Tertiary Prevention System for Congenital Heart Disease", Capital Citizens' Health Project Cultivation Project "Research and Demonstration Application of Key Technologies for Tertiary Prevention and Treatment of Congenital Heart Disease in Children in Beijing", Shenzhen Three Famous Projects "Integrated Management of Fetal Prenatal and Postnatal Care", etc. Certain experience has been gained, which can be promoted nationwide in a planned manner.